三鑫醫療(300453.SZ):擬對全資子公司四川威力生增資1.5億元
格隆匯 9 月 24日丨三鑫醫療(300453.SZ)公佈,公司於2020年9月24日召開了第四屆董事會第六次會議,審議通過了《關於向全資子公司四川威力生醫療科技有限公司增資的議案》,為加快四川威力生醫療科技有限公司(以下簡稱“四川威力生”)工程建設進度,儘快形成更大生產能力,董事會同意公司以自有資金人民幣1.5億元對四川威力生進行增資。本次增資完成後,四川威力生註冊資本將由5000萬元增加至2億元,公司仍持有其100%股權。
根據《公司章程》規定,本次增加註冊資本事項在董事會審批權限內,無需提交公司股東大會審議。本事項不涉及關聯交易,也不構成《上市公司重大資產重組管理辦法》規定的重大資產重組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.